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Rare heterozygous coding variants in the triggering receptor expressed in myeloid cells 2 (TREM2) gene,
conferring increased risk of developing late-onset Alzheimer’s disease, have been identiﬁed. We
examined the transcriptional consequences of the loss of Trem2 in mouse brain to better understand its
role in disease using differential expression and coexpression network analysis of Trem2 knockout and
wild-type mice. We generated RNA-Seq data from cortex and hippocampus sampled at 4 and 8 months.
Using brain cell-type markers and ontology enrichment, we found subnetworks with cell type and/or
functional identity. We primarily discovered changes in an endothelial gene-enriched subnetwork at
4 months, including a shift toward a more central role for the amyloid precursor protein gene, coupled
with widespread disruption of other cell-type subnetworks, including a subnetwork with neuronal
identity. We reveal an unexpected potential role of Trem2 in the homeostasis of endothelial cells that
goes beyond its known functions as a microglial receptor and signaling hub, suggesting an underlying
link between immune response and vascular disease in dementia.
 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Genome-wide association studies and genome sequencing have
identiﬁedmore than 25 Alzheimer’s disease (AD) risk loci, including
common, low-risk variants and rare moderate risk variants, in
addition to the classical risk variants in the apolipoprotein E (APOE)
gene (Guerreiro et al., 2013b; Hollingworth et al., 2011; Jonsson
et al., 2013; Lambert et al., 2013; Naj et al., 2011; Pimenova et al.,
2018; Steinberg et al., 2015). Although the identity of many of the
associated disease genes and the mechanisms by which they in-
crease risk remain unclear, there is evidence that they cluster
around the immune system, protein and lipid metabolism,x PO 80, De Crespigny Park,
969; fax: þ44 207 848 0866.
.uk (G. Carbajosa).
er Inc. This is an open access articespecially inﬂammatory response, endocytosis, and amyloid pre-
cursor protein (App) metabolism (Hardy et al., 2014; Naj and
Schellenberg, 2017; Villegas-Llerena et al., 2016). Many implicated
genes encode proteins that are highly expressed in microglia (ABI3,
PLCG3, TREM2, SPI1, BIN1, CD33, INPP5D, MS4A6A) and/or have a
role in the innate immune system in the brain (Huang et al., 2017;
Pimenova et al., 2018). One of these, TREM2 (triggering receptor
expressed on myeloid cells 2), has an AD-associated risk allele
(R47H) with an effect size in AD similar to that of ApoE4 (odds ratio
2.90e5.05) (Guerreiro et al., 2013b; Jonsson et al., 2013).
TREM2 function can be compromised as a result of rare non-
synonymous variants that cause Nasu-Hakola disease when both
alleles are affected (Numasawa et al., 2011; Ridha et al., 2004;
Soragna, 2003) or signiﬁcantly increase the risk of developing AD
(Guerreiro et al., 2013b; Jonsson et al., 2013; Sims et al., 2017),
behavioral variant frontotemporal dementia (Guerreiro et al.,le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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aphasia or occasionally Parkinson’s disease (PD) (Borroni et al.,
2014; Liu et al., 2016; Rayaprolu et al., 2013) when 1 allele is
affected. Evidence suggests TREM2 may be important for normal
brain remodeling, which peaks around adolescence (Chertoff et al.,
2013) and in later life in response to age-related damage or pa-
thologies. It is not clear whether the same signals or brain regions
are affected by TREM2 activity throughout life. In people where
TREM2 is compromised by complete loss of function, symptoms
begin in adolescence and tend to implicate frontal lobe dysfunction,
whereas in people with preservation of some normal TREM2 ac-
tivity, symptoms appear much later in life and implicate the hip-
pocampus (Giraldo et al., 2013). Although in both cases, progressive
white matter changes in the brain and dementia symptoms occur.
TREM2 is a receptor highly expressed on macrophages, including
microglia in the brain (Butovsky et al., 2014; Hickman et al., 2013;
Paloneva et al., 2002; Schmid et al., 2002). It appears to be an
important damage sensing receptor. It can respond to lipid and li-
poprotein species such as phosphatidyl serine (Cannon et al., 2012;
Wang et al., 2015), clusterin, and apolipoproteins, including APOE
(Atagi et al., 2015; Poliani et al., 2015; Yeh et al., 2016) and nucleotides
and anionic species such as heparin sulphate, proteoglycans, or other
negatively charged carbohydrates (Daws et al., 2003; Kawabori et al.,
2015; Kober et al., 2016), and is required for efﬁcient bacterial clear-
ance (N’Diaye et al., 2009). TREM2 signaling is propagated through
the adaptor protein DAP12, which activates a number of pathways
including Syk, P13 K, and mitogen-activated protein kinase, which
culminate in increased phagocytosis and expression of an anti-
inﬂammatory phenotype in microglia (Kleinberger et al., 2014;
Neumann and Takahashi, 2007; Peng et al., 2010; Poliani et al.,
2015; Takahashi et al., 2007). Loss of Trem2 function culminates in a
decrease in the number and activation of microglia in mouse models
of AD or in mice treated with cuprizone to damage myelin (Cantoni
et al., 2015; Ulrich et al., 2014; Wang et al., 2015). Trem2-deﬁcient
dendritic cells secrete more TNF-a, IL-6, and IL-12 compared with
wild-type (WT) cells, particularly when activated with lipopolysac-
charides suggesting there may be a shift toward cells expressing a
proinﬂammatory and potentially more damaging phenotype in the
absence of Trem2 (Hamerman et al., 2006; Turnbull et al., 2006).
However, not all ﬁndings are consistent. A recent report demon-
strated reduced AD pathology in an amyloid mouse crossed with a
Trem2 knockout (KO) mouse (Jay et al., 2015).
The main AD-associated TREM2 variant R47H has been shown to
alter glycosylation and trafﬁcking of the TREM2 protein between the
golgi and endoplasmic reticulumresulting in fewer functional TREM2
receptors in the cellmembrane and thus loss of TREM2 function (Park
et al., 2015). The presence of this variant also reduces the cleavage of
full-length TREM2 to a soluble extracellular fragment and, in both
TREM2riskvariant carriers and inpeoplewithAD, less soluble TREM2
is present in cerebrospinal ﬂuid (Kleinberger et al., 2014) suggesting
TREM2 dysfunction may be a common feature in AD and not just in
thoseADpatients carrying a loss of function variant. Notwithstanding
this, recent ﬁndings suggest that soluble form of the innate immune
receptor TREM2 levelsmaybe reducedor increaseddependingon the
stage of AD and variant (Brendel et al., 2017).
TREM2 and other late-onset AD susceptibility genes MS4A4A/
4 E/6A, CD33, HLA-DRB5/DRB1, and INPP5D are all part of a
distinctive brain coexpression module, which also contains the
signaling partner for TREM2, TYROBP, or DAP12 (Forabosco et al.,
2013; Hawrylycz et al., 2012; Zhang et al., 2013). This module ap-
pears to represent a biological network active inmicroglial cellswith
an innate immune function. It is signiﬁcantly perturbed in AD brain
(Forabosco et al., 2013; Hawrylycz et al., 2012; Zhang et al., 2013) and
remarkably contains fewer than 150 genes. This module shares
identity with peripheral macrophages (Forabosco et al., 2013), andmany of the genes in the module are also altered in AD blood cells
(Lunnon et al., 2012). Elevated expression of many of these genes,
particularly TREM2 appears to be associated with the emergence of
amyloid rather than Tau pathology in ADmouse models (Jiang et al.,
2014; Matarin et al., 2015). Both TREM2 and Tyrobp have also been
identiﬁed as major hubs in human APOE-expressing mice following
traumatic brain injury (Castranio et al., 2017).
Prominent voices in the ﬁeld of AD research are proposing that
to fully understand the etiology of AD, we have to go beyond
reductionist approaches and the amyloid cascade linearity and that
there is a need for studies that address the complex cellular context
of the disease, which involves interactions between different cell
types as the disease progresses across time and tissue (De Strooper
and Karran, 2016). It is suggested that temporal resolution can be
obtained from cohorts of mice at different stages of the disease.
Previous studies using a systems level approach on TREM2 have
lacked the aforementioned temporal resolution. Furthermore, the
use of microarrays to measure gene expression could have meant
that subtle effects are not detected. In our study, we tried to address
these concerns by proﬁling Trem2 KO mice gene expression using
RNA-Seq at 2 time points and tissues. We used brain cell markers to
infer cell type speciﬁcity and detected gene coexpresion dysruption
affecting a module with endothelial identity at an early stage that
causes widespread disruption of other cell-type subnetworks,
including a subnetwork with neuronal identity.2. Methods
2.1. Design
Brain tissue sampleswere obtained frommale Trem2KO andWT
control mice at 2 time points: 4 months and 8 months. These time
points span the onset and late disease stages inwell-established AD
mouse models (Matarin et al., 2015). Hippocampus and cortex were
selected because they represent tissues affected in AD at early and
late stages, respectively (Mastrangelo and Bowers, 2008; Matarin
et al., 2015). RNA-Seq was used to proﬁle the transcriptomes for
each sample. Two technical replicates were obtained for each sam-
ple. Expression data analyzed in this study are available at Gene
Expression Omnibus data repository from the National Center for
Biotechnology through accession number GSE104381.
Differential expression (DE) analysis allowed us to detect
changes in expression between time points and tissues. Coex-
pression analysis was performed to detect higher-level distur-
bances in gene expression networks. Enrichment analysis of the
results allowed us to detect functions and pathways more altered in
the absence of Trem2. Finally, the integration of cell type markers
enabled us to go further and not only detect time and tissue-speciﬁc
changes but also uncover how the interactions between different
cell types were affected and at which time point and tissue these
changes were occurring. Fig. 1A displays an overview of the
experimental and analytical workﬂow.2.2. Generation of Trem2-/- mice
The Trem2-/- mouse model (Trem2tm1(KOMP)Vlcg) was
generated by knocking a LacZ reporter cassette into the endogenous
Trem2 locus in place of exons 2 and 3 and most of exon 4, resulting
in a loss of Trem2 function and expression of the LacZ reporter
under the control of the Trem2 promoter, as described previously
(Jay et al., 2015). The mouse line was originally generated by the
trans-NIH KnockOut Mouse Project (KOMP). Frozen sperms were
obtained from the UC Davis KOMP repository, and a colony of mice
was established at Taconic, Cambridge City, MA, USA. Mice were
Fig. 1. Experimental design, analysis workﬂow and KO assessment. (A) Experimental design and analysis workﬂow. Transcriptome proﬁling of 8 WT and 8 Trem2 KO mice using
RNA-Seq. Read alignment to quantify transcripts was done using Kallisto. Different expression analysis was done using Sleuth. Coexpression network analysis was done using
WGCNA. Enrichment analysis was done with Enrichr. To estimate cell type associations with coexpression modules, gene markers were obtained from an external source (Zhang
et al., 2014). All the results were contrasted to infer time and tissue-speciﬁc changes caused by the absence of Trem2. (B) Trem2 and Treml1 isoforms expression levels. Trem2
ensembl transcripts consist of 2 coding transcripts, ENSMUST00000024791 and ENSMUST00000113237, and 2 noncoding, ENSMUST00000132340 and ENSMUST00000148545.
Treml1 only has one annotated coding transcript ENSMUST00000024792. Abbreviations: KO, knockout; Trem2, triggering receptor expressed in myeloid cells 2; WT, wild type.
G. Carbajosa et al. / Neurobiology of Aging 69 (2018) 151e166 153maintained on a B6 background and shipped to Eli Lilly and Co,
Indianapolis, IN, USA, for subsequent tissue collection.
2.3. Sample description and RNA-Seq Library construction
A total of 64 samples were used in the study. The hippocampus
and cortex were dissected from the left hemisphere of each mousebrain and snap frozen in liquid nitrogen. Tissues were homoge-
nized in Qiazol reagent and total RNA isolated using the RNeasy
Plus Universal Mini Kit according to the manufacturer’s protocol
(Qiagen). RNA integrity was measured for all samples using the
Bioanalyser Agilent 2100 series using RNA nano chip. All
sequencing libraries analyzed were generated from RNA samples
measuring an RNA integrity score 8.9. The Illumina TruSeq
G. Carbajosa et al. / Neurobiology of Aging 69 (2018) 151e166154mRNA stranded protocol was used to obtain poly-A mRNA from all
samples. Hundred nanogram of isolated mRNA was used to
construct RNA-seq libraries. Libraries were quantiﬁed and
normalized using the NEBNext mRNA Library prep kit for Illumina
and sequenced as paired-end 76 bp reads on the Illumina NextSeq
500 platform using technical replicates.2.4. RNA-Seq analysis
RNAseq reads were aligned to the mouse GRCm38 rel 79
reference transcriptome using Kallisto version 0.42.4 (Bray et al.,
2016). The reference transcriptome was downloaded from the
Kallisto project website (“http://bio.math.berkeley.edu/kallisto/
transcriptomes/” n.d.). A batch of quality control methods
implemented in the R sleuth package were applied, including
principal component analysis, MA plots, qq-plots, and varplot
(bootstrapping) (See Supplementary File 1). Quality control
revealed consistent quality, and no samples were removed. Dif-
ferential gene expression analysis was performed on transcripts
per kilobase million-normalized counts with the R sleuth package
version 0.28.1 (Pimentel et al, 2016; Pimentel et al., 2017). Mul-
tiple biological replicates were used for all comparative analysis
and a technical replicate for each of the samples. Signiﬁcant
genes, q-value  0.01, were used for gene ontology and pathway
analysis. Gene ontology and pathway analysis were performed
using the Enrichr database (Chen et al., 2013; Kuleshov et al.,
2016; Newhouse, 2017) and Process Network Tool in (Thomson
Reuters). Plots and graphics were generated using the sleuth
(Pimentel et al., 2016; Pimentel et al., 2017) and ggplot2 version
2.2.1 (Wickham, 2009) R packages. R 3.3.0 version was used.
The number of reads per replicate ranged from 16 to 40 million
reads (see Supplementary Table 1). The efﬁciency of the mapping
varied from 75% to 87% with the number of reads mapped ranging
from 13 million to 30 million. Each sample was proﬁled for 44,131
transcripts with 16,455 genes detected after quality control
ﬁltering. Principal component analysis revealed that samples
clustered by age and tissue (see Supplementary File 1). Quality
control revealed consistent quality, and therefore, all samples were
used in subsequent analyses.2.5. Gene network construction and module detection
For the coexpression analysis, we included all genes that were
expressed in at least one time point, condition, or tissue in the ﬁnal
set and with at least 10 reads in more than 90% of samples
(Langfelder and Horvath, 2008). Using these criteria, Trem2 is
retained for analysis, even though it is not expressed in the Trem2
KO mice. This left us with 14,920 genes (see Fig. 1A).
We used WGCNA version 1.51 to identify modules of coex-
pressed genes within gene expression networks (Langfelder and
Horvath, 2008). To construct the network, biweight mid-
correlations were calculated for all possible genes pairs. Values
were entered in amatrix, and the datawere transformed so that the
matrix followed an approximate scale-free topology (see
Supplementray File 2 for detailed information). A dynamic tree cut
algorithm was used to detect network modules (Langfelder et al.,
2008). We used signed networks to preserve the direction of cor-
relations. We ran singular value decomposition on each module’s
expression matrix and used the resulting module eigengene, which
is equivalent to the ﬁrst principal component (Langfelder and
Horvath, 2007), to represent the overall expression proﬁles of the
modules.
Cytoscape v3.5.1 was used to generate network maps of the
most highly correlated genes and modules (Shannon et al., 2003).2.6. Module matching between networks
Modules from the Trem2 KO network were matched to those of
the WT network using a hypergeometric test to identify the WT
module that has the most signiﬁcant gene overlap and its color was
then assigned to the KO module.2.7. Module preservation statistics
We applied both the module preservation Z summary and the
medianRank statistics to assess the module preservation from
different expression datasets (Langfelder et al., 2011). Unlike the
cross-tabulation test, Z summary not only considers the overlap in
module membership (MM) but also the density and connectivity
patterns of modules. In addition, for our study, network-based
preservation statistics only require MM that is identiﬁed in the
original datasets, reducing the variation coming from various pa-
rameters setting to identify newmodules in validation datasets. We
converted the transcript-level measurements into gene-level
measurements using the collapseRows R function (Miller et al.,
2011). We adapted the method used to select the most represen-
tative probe to select the most representative transcript. The tran-
script isoform within a gene that had the highest average
expressionwas used to represent that gene as it has been described
that it leads to best between-study consistency. Overall, 14,920
genes were retained in our preservation calculation.2.8. Module membership statistics
MMmeasures correlations between each gene and each module
eigengene, effectively measuring how strong is the connection of a
gene with the module it has been assigned to and to the other
modules too. We compared the correlation of the MM values be-
tween the WT and KO networks using 2 approaches using the
methods described by the WGCNA authors (Langfelder and
Horvath, 2008). The ﬁrst one uses all the genes to assess overall
conservation of the modules. The second one only includes the
genes assigned to themodules to assess “hub” conservation (i.e., are
the genes more strongly correlated to a module in one of the net-
works also strongly correlated to the module in the other network).2.9. DE tests for modules
We used student t-tests to statistically compare expression
differences between modules as suggested by the WGCNA authors
(Langfelder and Horvath, 2008).2.10. Integration of cell type markers
The top 500 most highly expressed genes for different brain cell
types (neurons, endothelial cells, astrocytes, microglia, oligoden-
drocyte precursor cells, newly formed oligodendrocytes, and mye-
linating oligodendrocytes) were selected from an RNA-Sequencing
transcriptome database (Zhang et al., 2014). Of these, 411
astrocytes, 386 endothelial cells, 316 microglia, 407 myelinating
oligodendrocytes, 394 newly formed oligodendrocytes, 390 oligo-
dendrocyte precursor cells, and 430 neurons marker genes could be
mapped to our dataset and were used in subsequent analyses. The
number of markers per cell type was divided by the total number of
markers present for that given cell type to take into account for any
bias in total number of cell markers available for different cell types.
The obtained values were multiplied by 100 to avoid working with
very small numbers.
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All animal procedures and experiments were performed in
accordance with the Institutional Animal Care and Use Guidelines
for Eli Lilly and Company. Protocol number 14e067.
3. Results
3.1. Analysis workﬂow and RNA-Seq assessment
In this study, we have applied an integrative approach for a
systems level characterization of how the absence of Trem2 affects
transcriptional expression (see the overview of the experimental
and analytical workﬂow in Fig. 1A). This approach aims to make our
results comparable with previous models of AD progression across
tissue and time (Matarin et al., 2015). For this purpose, we used
hippocampus and cortical regions to model progression across
tissue and 2 time points, 4 and 8months, tomodel progressionwith
age. We compared the transcriptomes of WT and KO mice identi-
fying differentially expressed genes, and we used coexpression
analysis to reveal changes in patterns of expression. To understand
the functional implications of those changes, we integrated term
enrichment analysis and brain cell-type markers obtained from an
external source (Zhang et al., 2014).
3.2. Trem2 KO mouse assessment shows that the Trem2 gene is
effectively silenced and the Treml1 gene is upregulated
To assess the efﬁciency of the Trem2 KO process, the levels of
expression of the Ensembl (Rufﬁer et al., 2017) annotated Trem2
transcripts were explored (Fig. 1B). Both protein-coding transcripts
and a small processed transcript were silenced in the KO. A non-
coding transcript containing a retained intron had higher expres-
sion in the KO, particularly at 4m in hippocampus. Treml1, the gene
immediately downstream of Trem2, was silent in the WT but
upregulated in the KO. The difference in Treml1 expression be-
tween WT and KO is the largest effect seen, even more so than that
of Trem2, at all time points and tissues (Fig. 1B). It was recently
described that this could be an artifact caused by the ﬂoxed
neomycin selection cassette (Kang et al., 2018) employed in the
generation of Trem2 KO mice used for this study. It is yet to
determine if this artifact is functionally meaningful but we will
interpret our results with caution because it is not possible to un-
mistakably determine if the effects seen in the KO are due to the
absence of Trem2, the upregulation of Treml1, or the combined
effect of both.
3.3. The effect on gene expression is temporal with a substantially
bigger number of DE genes at 4m
Initially, we explored gene expression differences across 4 and
8 months aged mice (see Fig. 1A, Supplementary Files 5 and 6 and
Supplementary Tables 2e5). A full list of differentially expressed
genes is available in Supplementray Tables 2e5. We found that the
number of DE genes between the WT and KO mice was 16-fold
higher at 4 months cortex, where a total of 1274 genes were
found to be differentially expressed, compared to 8 months cortex,
where the expression of 79 genes was altered. The same trend was
seen in the hippocampus, although fewer genes were differentially
expressed at the early time point 495 at 4 months compared with
time point 126 at 8 months.
The only substantial overlap in DE genes across time and tissue
was found at 4 months, where the hippocampus and cortex shared
277 DE genes (see Supplementary File 6). This representsmore than
half of the DE genes in the hippocampus but less than a quarter ofthe DE genes in the cortex. Among these are genes previously
associated with AD. For example, Rbm3, which has been shown to
mediate structural plasticity and have protective effects on cooling
in neurodegeneration (Peretti et al., 2015), is downregulated in the
KO. Nfya, which is also downregulated, has been described to have a
role in angiogenesis (Xu et al., 2016). Treml2, which was upregu-
lated in the cortex at 4 months and in both tissues at 8 months, has
been reported to contain variants with a protective effect in AD
(Benitez et al., 2014).
Besides the overlap at 4 months, there is a reduced number of
genes that are differentially expressed in more than one time point
and tissue (see Supplementary Tables 6 and 7). Only Trem2 (as
expected), Treml1, Grp17, and Fam107a are differentially expressed
at all time points and tissues. Interestingly, Grp17 has been previ-
ously associated with Nasu-Hakola disease (Satoh et al., 2017), a
disease characterized by homozygous loss of function of Trem2 or
its signaling partner Tyrobp (Paloneva et al., 2002), and has been
successfully targeted with a marketed antiasthmatic drug that re-
duces neuroinﬂammation and elevates hippocampal neurogenesis
resulting in improvements to learning and memory in older ani-
mals (Marschallinger et al., 2015). Fam107a, also known as Drr1, has
been described as a stress-induced actinebundling factor that
modulates synaptic efﬁcacy and cognition (Schmidt et al., 2011) and
has also been connected to brain cancer (Dudley et al., 2014; Le
et al., 2010).
3.4. Gene ontology enrichment analysis of DE genes shows time-
and tissue-speciﬁc enrichment of processes related to AD
Ontology analysis showed enrichment for genes involved in
response to unfolded proteins and ubiquitination-related functions
at 4 months in both tissues (Table 1; also see S8 Table). Both
functions were driven mainly, but not exclusively, by the differen-
tial expression of genes of the DnaJ family (DnaJA2 and DnajB2) and
heat shock proteins, for example, HspA8 and Hsph1. Enrichment for
“response to heat” was signiﬁcant in the hippocampus and was
driven by Camk2g and Camk2b, members of the calmodulin-
dependent protein kinase subfamily involved in calcium signaling.
A similar trend was seen in the cortex.
At 8 months, both tissues showed enrichment for membrane
targeting-related functions, driven mainly by ribosomal proteins
such as Rpl10, but there were also differences between them. In
hippocampus, there was enrichment for “regulation of macro-
autophagy” driven by Uchl1, which has been previously implicated
in AD, and also for “organelle transport along microtubule” driven
by Cdc42 and CopG1. In the cortex, enrichment for “cellular
response to vascular endothelial growth factor stimulus” was
driven by Flt1 (also know as VEGFR1) and Dll4, which have been
both described as having a role in endothelial sprouting (Eilken
et al., 2017; Pitulescu et al., 2017).
3.5. Trem2 WT and KO gene coexpression networks analysis
identiﬁes modules with cell type and/or functional identities
We generated 2 multitissue and multiage networks, one for WT
and one for the KO, and matched the latter to the former (see
Methods and Fig. 2). The WT network consisted of 8 modules, each
containing between 127 and 6477 gene members. The KO coex-
pression network comprised 9 modules ranging from 204 to 5213
genes.
Gene ontology and pathway analysis were used to assign bio-
logical signiﬁcance to each module (see S9 Table). In the majority of
cases, WT and KO modules were enriched for similar terms. In both
WT and KO, the blue module was enriched for functions related to
synaptic transmission and neurotransmitter secretion. Similarly,
Table 1
Summary of ontology enrichment for the differentially expressed genes across time points and tissues
GO BP-enriched term Benjamini-Hochberg corrected p-value
4 mo 8 mo
Hippocampus Cortex Hippocampus Cortex
Response to unfolded protein (GO:0006986) 0.0003578 0.0001455 0.1678 0.1767
ATF6-mediated unfolded protein response (GO:0036500) 0.01047 0.002142 NS NS
Regulation of cellular response to heat (GO:1900034) 0.005745 0.0793 0.4287 0.3149
Regulation of protein ubiquitination (GO:0031396) 0.01939 0.6671 NS 0.1239
Positive regulation of proteasomal ubiquitin-dependent protein catabolic
process (GO:0032436)
0.483 0.0007589 NS NS
SRP-dependent cotranslational protein targeting to membrane (GO:0006614) 0.9078 1 4.71Ee12 0.05501
Translation (GO:0006412) NS 1 2.27Ee10 0.07171
Regulation of macroautophagy (GO:0016241) NS 0.6991 0.005104 0.3018
Organelle transport along microtubule (GO:0072384) NS NS 0.01932 NS
Cellular response to vascular endothelial growth factor stimulus (GO:0035924) 0.5601 0.4068 NS 0.06581
Adjusted p-values obtained using a Fisher exact test with Benjamini-Hochberg method for correction for multiple hypotheses using Enrichr (Chen et al., 2013).
Key: ATF6, activating transcription factor 6; BP, biological process; GO, gene ontology; SRP, signal recognition particle.
G. Carbajosa et al. / Neurobiology of Aging 69 (2018) 151e166156the brown module was enriched for mRNA transport and process-
ing functions in both networks. The tan module was enriched for
functions related to translation, protein targeting tomembrane, and
mRNA catabolism. The turquoise module was strongly associated
with ncRNA, mitochondrial-related functions, and house-keeping
functions. The red module was associated with RNA splicing and
cell cycle-related functions. Conversely, the midnight blue module
showed different functions in the WT and KO networks. In the WT,
the module was associated with deubiquitination, and in the
KO, most of its associated functions were related to synaptic
transmission.
We used brain cell-type markers (Zhang et al., 2014) as a proxy
to test cell-type enrichment for each module (see Methods and
Figs 3, 4). TheWTand KO gene expressionmodules have similar cell
type proﬁles (Supplementary File 3). The results of the enrichment
for ontology terms support those of the cell type enrichment
analysis, for example, the blue module is enriched for neuron cell
markers and for neuronal functions like synaptic transmission. The
modules that had a clearer cell type identity were the mentioned
blue module with a neuronal identity, the light cyan module with
endothelial identity, and the tan module with a microglial identity.
3.5.1. KO-speciﬁc coexpression modules emerge notwithstanding
broad conservation between WT and Trem2 KO coexpression
networks
After identifying the modules in the 2 networks, we wanted to
compare how well preserved they were. Given the cell type and
functional assignments done previously, we could potentially
identify interesting functional or cell-type perturbations between
the 2 by looking at the differences between the network modules.
Fig. 2A highlights the direct comparison of the WT and KO coex-
pression networks. It represents the number of genes for each
module in each of the coexpression networks and the number of
those genes that overlap with the modules in the other network. To
formally assess the preservation of the WT modules in the KO
network and vice versa, we calculated their Z summary preserva-
tion scores and median rank preservation values (Fig. 2B, C)
(Langfelder et al., 2011) (see Methods section).
Most WT modules have a KO counterpart, with the exception of
the WT pink module. Similarly, all the KO coexpression modules
had aWT counterpart, except the KO magenta and yellowmodules.
The WT light cyan module was ranked as the least preserved
module. TheWT tanmodule hadoneof the lowest Z summary scores
and rankings, as does its KO counterpart. The tan module was of
particular interest because it contained Trem2 and its signaling
partner Tyrobp and, consistently with Trem2 being expressed in
microglia,was assigned amicroglial identity using cell typemarkers.The KO magenta, midnight blue, yellow, and brown had rela-
tively lower Z summary values but we could not consider any
module as not “preserved” because they all had Z summary scores
higher than 10 (Horvath, 2011).
Z summary scores were inﬂuenced by module size, which can
explain the apparent contradiction of the midnight blue module be-
ing at the same time the best ranked for preservation and the 1 with
the lower Z summary score. This module is markedly different be-
tween the WT and KO, partially because the color assignment of the
KO midnight blue module is based on 26 overlapping genes (only 5%
of the 529 genes in the module) with theWTmidnight blue module.
To further study the module preservation between the 2 net-
works, we used MM values. The modules with the lowest correla-
tions in MM between the WT and KO were the light cyan and tan
modules (see Supplementary Files 7 and 8), the same ones that had
overall lowest preservation scores. MM effectively measures how
strong is the connection of a gene with the module it has been
assigned to, calculating the correlation between the gene and the
module eigengene. The genes with the highest MM are the most
highly connected genes within the module and are referred to as
“hubs”. This correlation is calculated not only for the module it has
been assigned to but also for the other modules too so it is useful to
compare different networks where the genes may have been
assigned to different modules (more details in the Methods sec-
tion). Despite broad conservation, there were modules that could
not be matched between the 2 networks. The WT pink module had
no KO counterpart, but it had a relatively high Z summary score
compared with the rest of the modules(see Fig. 2B) and was one of
the modules with the highest MM correlation with the KO network
(cor 0.89, p-value<0.01; see Supplementary File 8). Interestingly, it
was enriched for extracellular matrix organization and exosome-
related functions and both endothelial and microglia cell type
markers. Furthermore, the pink module top hub gene Col8a2, en-
codes a protein whose absence has been described to produce
progressive alterations in endothelial cell morphology and cell loss
(Jun et al., 2012). Npc2, one of the genes causing frontotemporal
dementia when mutated (Zech et al., 2013), is also part of this
module.
In the KO network, the magenta and yellow modules were not
matched to any WT modules and had low Z summary scores.
Seventy-two percent of magenta module genes overlap with the
light cyan endothelial module, one of the least preserved modules.
Nearly 20% of the genes of the yellow module ovelap with the tan
module, the other least preserved module, and 60% of them overlap
the blue module with neuronal identity. We considered that this
deserved further inspection and wewill look at them inmore detail
in the following sections.
Fig. 2. Module preservation between WT and Trem2 KO networks. (A) Correspondence of WT set-speciﬁc modules andTrem2 KO-matched modules. Each row of the table cor-
responds to one WT set-speciﬁc module (labeled by color as well as text), and each column corresponds to one KO module. Numbers in the table indicate gene counts in the
intersection of the corresponding modules. Coloring of the table encodes $-ylog(p)$, with p being the hypergeometric test p-value for the overlap of the 2 modules. The stronger
the red color, the more signiﬁcant the overlap is. The table indicates that most WT set-speciﬁc modules have a KO counterpart. (B) Preservation of WT modules in KO network. The
left panel shows the composite statistic median rank versus module size. The higher the median rank the less preserved is the module relative to other modules. Since median rank
is based on the observed preservation statistics (as opposed to Z statistics or p-values), it is independent on module size. The right panel shows the composite statistic Z summary. If
Z summary >10 there is strong evidence that the module is preserved (Langfelder et al., 2011). If Z summaryytextless 2, there is no evidence that the module preserved. Note that Z
summary shows a strong dependence on module size. (C) Preservation of KO modules in WT network. The same as (B) but in this case, we assess the preservation of the modules
obtained in the KO network to see how preserved they are compared to the ones obtained in the WT network. Abbreviations: KO, knockout; Trem2, triggering receptor expressed in
myeloid cells 2; WT, wild type. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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Fig. 3. Summary of KO emerging modules top hubs and cell type and ontology enrichment. For each module considered, the list of the genes with the strongest correlation within its
module, top hubs, is shown together with a list of ontology terms representative of the module function enrichment with its adjusted p-value (see Methods). The cell type identity of
the network modules is inferred using gene markers enrichment. Each panel displays the proportion of markers for each cell type present in the module. The counts of the number of
markers per cell type was divided by the number of markers present for that given cell type to take into account a possible bias (see Methods for further details). The method allows us
to approximate the proportion of each cell type that conform a module. For example, the WT, the blue module is the module with the highest proportion of neuron markers, although
it has also a high proportion of other cell-type markers, and the light cyan is enriched for endothelial cell markers. The cell types considered are astrocytes (AS), endothelial cells (ET),
microglia (MG), myelinating oligodendrocytes (MO), newly formed oligodendrocytes (NO), oligodendrocyte precursors cells (OP), and neurons (NE). (A) Emergence of KO yellow
module by an increase in expression correlation of parts of the WT blue and tan modules. (B) Emergence of KO magenta module by the disruption of the WT light cyan module.
Abbreviations: KO, knockout; WT, wild type. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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processes, microglia cell markers, and genes previously implicated in
different dementias
The KO yellowmodule contained genes overlappingmostly with
the WT blue and WT tan modules (see Fig. 2A). We looked at the
different gene ontology and cell type-enrichment proﬁles and top
hub genes of these modules to further understand the yellow
module emergence in the KO (see Fig. 3A).
The WT blue module was enriched for neuron cell markers
and terms associated with neuronal cell functions, such asneurotransmitter secretion and synaptic transmission. Its top hub
gene, Prkar1b, has been previously linked with neurodegeneration
(Wong et al., 2014) and the second one, Clstn1, has been shown to
be associated with pathogenic mechanisms of AD (Vagnoni et al.,
2012).
The WT tan module was enriched for microglia cell-type
markers and for translation-related ontology terms and its top
hub gene was the ribosomal protein, Rpl18a.
The KO yellowmodule that emerged as parts of theWT blue and
WT tan module had a cell marker proﬁle very similar to the WT tan
Fig. 4. Disruption of the modules interconnectivity. (A) Network view of the gene correlations higher than 0.5 in the WT (left panel) and the KO (right panel). Gene colors represent
the module where they have been assigned. Some genes appear as not connected to a module they are assigned to because their correlation to other members of the module is
lower than 0.5. Modules are labeled according to their enrichment of cell-type markers. The light cyan module, enriched for endothelial cell markers, is closely connected with the
blue module, enriched for neuron cell markers, and in turn connects it to the modules enriched in glia markers in the WT. In the KO, this connection is weakened when the majority
of endothelia cell marker genes become members of a newly formed magenta module that is no longer strongly correlated with the blue module. The most correlated gene within
each module, the top hub, is shown in an ellipse ﬁlled with the color of the module it belongs to. The top hub of the light cyan in the WT is Ttbk1, Tau Tubulin Kinase 1, which
regulates phosphorylation of tau, and in the KO its place is taken by App, the gene that codes for the amyloid precursor, both proteins central to the Alzheimer’s pathology. The blue
module expression association with age is decreased in the KO network but not in the WT (2 tailed t-test with Welch modiﬁcation, pval ¼ 0.0036) and the midnight blue module
expression is increase with age in the KO (2 tailed t-test with Welch modiﬁcation, pval ¼ 0.017) but not in the WT. (B) Differential expressed genes per module across time and
tissue. In each of the 4 panels, the percentage of geneswithin each module that are DE respect the total number of genes in the module is represented for that tissue and time point.
The light cyan module is the module with the higher proportion of DE genes at 4 months in both tissues in the WT. The magenta module, which can be considered a light cyan
spinoff because the majority of its genes have a counterpart in that module (see Fig. 2A), is in turn the module with the higher proportion of DE genes in the KO. Differences in
expression affect different modules in different tissues at 8 months, the tan module being the most affected in the hippocampus while the changes in the cortex are predominantly
affecting the magenta module as it is also the case at 4 months. Abbreviations: App, amyloid precursor protein; DE, differential expression; KO, knockout; WT, wild type. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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uitin-, and catabolism-related processes.
Interestingly, the KO yellowmodule top hub gene was Atp6v0c.
This gene encodes a component of vacuolar ATPase (V-ATPase), a
multisubunit enzyme that is necessary for intracellular processes
receptor-mediated endocytosis and synaptic vesicle proton
gradient generation (Lee et al., 2010). Atp6v0c has been shown to
alter autophagy-lysosome pathway function and metabolism of
proteins that accumulate in neurodegenerative disease (Mangieri
et al., 2014) and has been described as a promising target for
therapeutic development (Higashida et al., 2017). Other genes
previously associated with different forms of dementia form part
of this module. Mapt, the gene that encodes the tau protein, which
has been associated with numerous types of neurodegenerative
disorders (Spillantini and Goedert, 2013), becomes strongly asso-
ciated with the module. Pink1, a gene that causes PD when
mutated, is also strongly associated, as it is Sqtsm1, a gene
involved in sporadic amyotrophic lateral sclerosis pathology
(Fecto, 2011).
Altogether, the characteristics of the yellow module relate to
known mechanisms involved in the pathology of different types of
dementias.
3.5.3. The KO magenta module is enriched for endothelial cell
markers and functions
The KO magenta module emerged from the disruption of the
WT light cyan module as can be seen from the module overlap in
Fig. 2A. Over 72%, 148 of 204, of the genes in the KO magenta
module overlapped with those of the WT light cyan module.
As we did before for the yellow module, we looked at the
different enrichment proﬁles and top hub genes of these modules
to further understand the module emergence in the KO (see
Fig. 3B).
The WT light cyan module was enriched for endothelial cell
markers and terms associated with endothelial cell functions, like
angiogenesis, and also for other functions related to AD such as
phagocytosis and response to unfolded protein. Its top hub gene
Ttbk1(tau tubulin kinase 1), whose encoded protein is a neuron-
speciﬁc serine/threonine and tyrosine kinase that regulates phos-
phorylation of tau, has been implicated in both the pathology of
amyotrophic lateral sclerosis (Liachko et al., 2014) and AD
(Vázquez-Higuera et al., 2011).
When the light cyan module broke up its KO counterpart
became enriched for ubiquitin- and catabolism-related processes.
TheWT hub gene Ttbk1, lost its hub status in the KOmodule, where
the top hub became App, the amyloid precursor gene. It is also
worthmentioning that in the KO, one of the top hub genes, the third
one, (see Fig. 3B) is Atp6v0a1, which is one of the components of the
vacuolar ATPase together with Atp6v0c, the top hub of the yellow
module.
The module was not enriched for endothelial cell-type markers
anymore but shifted toward an oligodendrocyte identity. This was
caused by the vast majority of endothelial cell markers moving to
the new magenta module, which was signiﬁcantly enriched for
genes with blood vessel development function. The magenta
module top hub, Ptprb, is also reportedly involved in the estab-
lishment of endothelial cell polarity and lumen formation
(Hayashi et al., 2013). Interestingly, Flt1 (also known as vascular
endothelial growth factor receptor 1) was another top hub in the
magenta module. Flt1 has been described to have a role in motor
neuron degeneration (Poesen et al., 2008). Most importantly, the
disruption of the light cyan module in the KO network suggested
that endothelial cells become dyscoordinated in the absence of
Trem2, the overexpression of Treml1, or when both effects are
combined.3.5.4. Dyscoordination of the endothelial module weakens neuron
module and glia module coexpression
To help us visualize better the differences between the WT and
KO networks, we plotted the coexpression networks with genes
colored by their module assignment, including only correlations
stronger than 0.5 (see Fig. 4A). In this way, we could see how the
disruption of the endothelial module in the KO network weakens
the connection of the whole network in general and in particular
the connections between the neuronal subnetwork and the mod-
ules with glial identity.
In the WT, the light cyan module (enriched for endothelial cell
functions and markers) was connected on one end with the blue
module (enriched for neuron functions and cell markers) and on
the other end, the light cyan endothelial module connected with
other modules enriched for glia markers and functions. In partic-
ular, the WT endothelial subnetwork was connected with the
brown module, which is mainly enriched for myelinating oligo-
dendrocytes and astrocytes. In the KO, these connections were
weakened by the endothelial module disruption. The KO light cyan
module counterpart remained strongly connected to the neuron
module and App became its top hub gene. The KO-speciﬁc magenta
module, which has the biggest proportion of endothelial gene
markers lost to the light cyan module in the KO, lost the strong
connection to the neuron module but remained correlated with the
brown module.
Interestingly, the new KO yellow module, enriched for protea-
some functions and genes previously associated with different
types of dementias, was also strongly correlated to the neuron
module.
We can also see in Fig. 4A how the midnight blue module is
markedly different between the WT and KO and is strongly asso-
ciated with the blue neuronal module in the KO. The KO midnight
blue module was enriched for neuron markers but also for the
gamma-aminobutyric acid signaling pathway (see S9 Table). While
the blue module expression decreases with age in the KO (t-test
with Welch correction, p ¼ 0.004), the expression of the midnight
blue increases (t-test with Welch correction, p ¼ 0.02) (see
Supplementary File 4). Interestingly, gamma-aminobutyric acid
signaling has been described to be increased in 5xFAD Alzheimer’s
mouse models and its reduction has been described to rescue the
impairment of long-term potentiation and memory deﬁcit (Wu
et al., 2014).
Mapping the differentially expressed genes to the modules ob-
tained in the previous section, we were able to visualize which
modules are affected at different ages in different tissues (see
Fig. 4B). At 4 months, most of the changes in expression in both
hippocampus and cortex affected the light cyan module in the WT
or the magenta module, product of the WT light cyan disruption, if
we look at the KO network. This points to the endothelial module
disruption being an early event. The light cyan module is enriched
for response to unfolded protein gene ontology terms in theWTand
for ubiquitination in the KO. This is consistent with what we found
in the enrichment analysis for genes being differentially expressed
at 4 months (described in Table 1). At 4 months, the rest of the
modules were broadly affected to a similar extent in both tissues.
Notable exceptions are the WT-speciﬁc pink module affected spe-
ciﬁcally in the cortex at 4 months and the yellow KO module that
shows larger differences at 4 months in the cortex, although not as
dramatically as the pink module.
At 8 months, there was a very different picture with changes in
expression affecting different modules in different tissues. The tan
module is the more affected in the hippocampus. Again, consistent
with the enrichment analysis performed previously for the differ-
entially expressed genes, we ﬁnd enrichment for macroautophagy
in both the tanmodule and list of differential expressed genes at 8m
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affected in the cortex. This again agrees with the enrichment for
“cellular response to vascular endothelial growth factor stimulus”
speciﬁcally in the list of differentially expressed genes at 8 months
cortex.
Overall, we found that the absence of Trem2, or potentially the
overexpression of Treml1 or the combined effect of both, in
microglia produces a ripple effect that provokes the disruption of a
subnetwork of genes enriched for endothelial cell genemarkers and
functions at an early time point, aged 4 months, with the effect
being stronger in the cortex at this early time point. At a later stage,
aged 8 months, cortex and hippocampus are affected differently
with the subnetwork of genes with microglial identity being more
perturbed in the hippocampus. These are time- and tissue-speciﬁc
effects that evolve with age.4. Discussion
Many risk genes contributing to dementia appear to have
pleiotropic effects. Rare loss of function variants in the TREM2 gene
can cause Nasu-Hakola disease when both alleles are affected
(Paloneva et al., 2000) or increase the risk to develop AD, PD, or
frontotemporal dementia in heterozygous carriers (Guerreiro et al.,
2013b; Jonsson et al., 2013). Further study of the complexmolecular
consequences of the absence of TREM2 could have a big impact on
our understanding of AD pathogenesis from a systems level view
(De Strooper and Karran, 2016). We generated RNA-Seq data to
proﬁle the hippocampus and cortex at aged 4 and 8 months to
explore the temporal and spatial consequences of Trem2 absence.
Differentially expressed genes were enriched for functions related
to AD and other forms of dementia. Furthermore, WGCNA analysis
coupled with enrichment for cell-type markers highlighted the
disruption of a coexpression module with a strong endothelial
identity. The absence of Trem2 in microglia appears to generate a
ripple effect that causes the disruption of an alignment between
endothelial cells and microglia affecting the coordination of neu-
rons and glia. Interestingly, this suggests a new role for Trem2
beyond its known functions as a microglial receptor and signaling
hub, linking the immune response with vascular consequences as
potential underlying causes of AD.
Our study involved expression proﬁling of 8 Trem2 KO and 8WT
mice using RNA-Seq. We sampled the hippocampus and cortex at
4 months and 8months of age. This allowed us tomodel the disease
progression across tissue and time and enables results to be
compared with previous expression proﬁling of transgenic mice
that develop amyloid or tau pathology (Matarin et al., 2015). Sur-
prisingly, the level of expression of Trem2 in theWTmice increases
from 4 months to 8 months in both tissues, at least for the most
highly expressed isoform. The differences may be attributed to the
use of RNA-Seq, which let us consider each isoform independently.
In fact, of the 2 protein-coding isoforms included in Ensembl, we
only detect signiﬁcant differential expression between 4 months
and 8 months for Trem2-201. As previously noted, microglia
exclusively express TREM2 in the brain (Ulrich et al., 2017), and the
increased levels of expression may reﬂect an increase in microglia
density with age (Conde and Streit, 2006). Other differential effects
between 4 and 8 months were also found. Nearly 1300 genes had
signiﬁcant differential expression at 4 months, which was reduced
to only 79 genes by 8months. Interestingly, the number of DE genes
was greater in the hippocampus than in the cortex at 8 months
suggesting a shift in dominance in Trem2 activity between brain
regions. These alterations follow a regional distribution that is
consistent with that of Nasu-Hakola, whose pathology affects
center in the cortical region earlier in life than AD, which has amuch later onset and centers at least initially in the hippocampus
(Ridha et al., 2004).
Surprisingly, the Treml1 gene appears to be upregulated across
all times and tissues. This may be because Trem2 normally inhibits
Treml1 expression or, alternatively, is an artifact of knockdown as
has been previously suggested (Kang et al., 2018). Nevertheless, it is
one of the few effects that are consistent across ages and tissues.
Furthermore, the upregulation of Treml1 is the largest effect we see.
Therefore, our results should be interpreted as either the conse-
quences of knockdown of Trem2, increase in Treml1, or both
together. This is an important ﬁnding that should be taken into
account on all studies using the same Trem2 KO mice used in our
study. To completely disentangle if the effects, especially in the
endothelial or other nonmicroglial cell types, can be interpreted as
an effect of Trem2, the distribution of expression and effects of
overexpressing Treml1 should be established. There is further
justiﬁed interest in the study of TREML1 expression as it has been
recently described that its upregulation may have a protective ef-
fect in AD with high levels of both TREM2 and TREML1 associated
with decreased disease risk (Carrasquillo et al., 2016). Interestingly,
the authors of the study propose, as we do here, a possible link
between neuroinﬂammation and vascular homeostasis as related
mediators of neuronal protection and injury in AD that involves
both TREML1 and TREM2.
Our WGCNA coexpression analysis coupled with cell brain cell-
type markers (Zhang et al., 2014) used as a proxy of cell-type
enrichment helped us to identify modules with both functional
and cell type identities. We found a module, blue, enriched for
synaptic transmission ontology terms had the highest enrichment
for neuronal markers. We also identiﬁed a module that contained
Trem2 and Tyrobp and was mostly enriched for microglia and
myelinating oligodendrocytes. The module containing Trem2 and
Tyrobp in our study is larger and has only modest gene overlap
compared to what was found in previous brain coexpression
network analyses (Forabosco et al., 2013; Zhang et al., 2013). Dif-
ferences are to be expected. Previous studies involved the analysis
of postmortem human control and/or AD brain tissue, and in both
cases, expression was proﬁled using microarray data. Nevertheless,
some of the key genes such as Fcer1g and Ly86 identiﬁed in the AD
immune module (Zhang et al., 2013) and Cxcr1 are present in the
Tyrobp module in our study or, as is the case of Cxcr1, in the
phagocytic yellow module that is speciﬁc to the KO network.
This emerging KO yellow module, which draws its genes from
the module with neuronal identity and the module containing
Trem2 and Tyrobp, was enriched in catabolic, proteasome, and
degradation associated functions. Interestingly, its top hub is
Atp6v0c, a gene that encodes a component of vacuolar ATPase, a
multisubunit enzyme that is necessary for intracellular processes
receptor-mediated endocytosis and synaptic vesicle proton
gradient generation (Lee et al., 2010), and has been described to
alter autophagy-lysosome pathway function and metabolism of
proteins that accumulate in neurodegenerative disease (Mangieri
et al., 2014) and has been proposed as a possible target gene for
therapy (Higashida et al., 2017). Furthermore, a number of genes
that have previously associated with dementia form part of this
module. Mapt, the gene encoding for the tau protein associated
with different types of neurodegenerative disorders (Spillantini and
Goedert, 2013), Pink1, a gene that can cause PD when mutated, and
Sqtsm1, a gene involved in sporadic amyotrophic lateral sclerosis
pathology (Fecto, 2011), are all part of this module suggesting that
all these neurodegenerative pathologies may share an underlying
molecular mechanism in which Trem2 plays a central role.
The WT light cyan module (enriched for phosphorylation
regulation, angiogenesis and protein processes, and junction-
related cellular compartments) was disrupted in the KO, showing
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module as a consequence. The KO-speciﬁc magenta module was
enriched in angiogenesis, similarly to the WT light cyan module
with whom it shares most of its genes, but it was not enriched for
phosphorylation regulation. The top hub gene in the WT light cyan
module was Ttbk1 (tau tubulin kinase 1) but in the disrupted KO
module App, the App becomes the top hub status, while the top hub
in the magenta module is Ptprb, which plays an important role in
blood vessel remodeling and angiogenesis. This disruption suggests
that Trem2 provides a link between endothelial cells and neurons
that appears essential to the survival of neurons. When the coor-
dination between the 2 falters, App drives a subnetwork of genes
involved in catabolic processes that is closely associated with the
neuronal subnetwork. As pointed out before, it is also possible that
Treml1, or both Trem2 and Treml1 acting together, may have a role
in the effects we see. This ﬁnding also points to a role of Trem2 in
the mechanisms behind the increased risk of dementia caused by
vascular damage (Mantzavinos and Alexiou, 2017) and could also
help explain the brain blood vessel damage described in cases of
Nasu-Hakola disease (Kalimo et al., 1994).
The changes affecting the module with endothelial identity
described previously occurred mainly at 4 months in both tissues,
but the effect was strongest in the cortex. These ﬁndings are
consistent with human studies on AD where early changes are
described in the prefrontal cortex region, for example, changes in
monoamine oxidase A and B (Kennedy et al., 2003) and these
correlatewith Braak stage (Braak and Braak,1997). At 8 months, the
changes are different from 4 months. A more phagocytosis-
dominated module is altered in the hippocampus perhaps coin-
ciding with the emergence of AD pathologies such as plaque
deposition. Somewhat surprisingly, a number of complement genes
are differentially expressed at 4 months in this module, C1qb in the
hippocampus and C1qa in the cortex, but not at 8 months, where
they lose their previous associationwith the module having neuron
identity. The complement system becomes activated in response to
the presence of amyloid and is therefore a pathological hallmark of
AD (Lui et al., 2016).
To conclude, we have found that the timing and magnitude of
the effects described in the Trem2 KO mice is different for different
brain regions. Overall, there were more changes in the cortex in
younger mice capturing what is observed in Nasu-Hakola disease,
which is characterized by frontotemporal dementia and blood
vessel dysfunction (Kondo et al., 2002), while the hippocampus in
older mice had more changes mirroring (R. Guerreiro et al., 2013b;
Jonsson et al., 2013)the vulnerability of the hippocampus in later
onset AD (Mastrangelo and Bowers, 2008; Matarin et al., 2015).
WGCNA analysis and brain cell-type marker integration revealed
links between several molecular processes previously described to
play a part in AD pathology. In our Trem2 KOmice, a central role for
amyloid processing emerged, as did changes in phagocytosis and
altered vascularity. This may reﬂect a more complex interplay be-
tween an absence of TREM2 and its effects in different tissue and
time and underlines the importance of considering the impact of
disease and risk genes on the whole brain network when exploring
cause, effect, and developing treatments. It will be important to see
if these ﬁndings can be replicated in people carrying the R47H-risk
variant associated with increased risk for AD (Guerreiro et al.,
2013b; Jonsson et al., 2013).
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